Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
MRI is particularly valuable in pediatric care due to its non-invasive nature
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups, supporting a broad range of oral dosing applications
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
Subscribe To Our Newsletter & Stay Updated
